AMERICAN JOURNAL OF BIOSCIENCE AND CLINICAL INTEGRITY
https://biojournals.us/index.php/AJBCI
ISSN: 2997-7347

Article

Changes in the Body of a Pregnant Woman as a Result of Hyperthyroidism

Abduganiyeva Malika Bekzod qizi[1], Togayeva Gulnora Siddikovna[2]

[1] Student of the 440th group of the Faculty of Medicine, Samarkand State Medical University
[2] Assistent, Department of Endocrinologi, Samarkand State Medical University, Samarkand , Republic of Uzbekistan

*Correspondence: -

Citation: Bekzod qizi, A. M & Siddikovna, T. G. Changes in the Body of a Pregnant Woman as a Result of Hyperthyroidism. American Journal Of Bioscience And Clinical Integrity 2026, 3(2), 51-55

Received: 10th Nov 2025
Revised: 21th Dec 2025
Accepted: 01th Jan 2026
Published: 14th Feb 2026

Abstract: Pregnancy with hyperthyroidism is a major clinical endocrine disorder, which seriously affects the physiological state and development of the mother and fetus. Sustained overproduction of thyroid hormone changes metabolic, cardiovascular, thermal and immune response function, adding maladaptive traits to the normal physiologic responses characteristic of pregnancy. Given that pregnancy by itself causes a significant hormonal and hemodynamic modification, differentiating between abnormal hyperthyroidism and gestational thyroid fluctuations can be difficult for the physician. This article reviews the systemic changes in a pregnant patient with hyperthyroidism, specifically the metabolic, cardiovascular ,hematologic, and obstetric outcomes. Emphasis is given to pathophysiological mechanisms, maternal–foetal interactions, and clinical implications for observation and management. Understanding these physiological adaptations is crucial for preventing adverse outcomes such as preeclampsia, preterm delivery, fetal growth restriction and neonatal thyroid dysfunction. Hyperthyroidism in pregnancy is characterized by dramatic changes in metabolism, cardiovascular and endocrine function, all potentially affecting the health of both mother and fetus. Excessive thyroid hormone overstimulates resting metabolic activity, heart work and nutrients utilization as it adds to the normal physiological states of gestation. There is evidence that untreated or suboptimally treated hyperthyroidism leads to adverse obstetric outcomes such as miscarriage, preterm birth, and low-birth-weight newborns and that the infants have an increased incidence of neonatal thyroid dysfunction. This review compiles the current knowledge on systemic manifestations of maternal hyperthyroidism, focusing on mechanisms underlying metabolic alterations, cardiac stress and immune modulation. In the following we focus on clinical management and intervention measures directed at reducing maternal and fetal risks.

Keywords: Hyperthyroidism, Pregnancy, Thyroid hormones, Maternal physiology, Fetal development, Graves' disease, Gestational thyrotoxicosis, Endocrine adaptation

Introduction

Pregnancy triggers massive morphological and functional changes in the body to facilitate fetal development and maternal adaptation. These include changes in blood volume, cardiac output, immunological tolerance, and intricate hormonal adaptations. In a seminal study, thyroxin induced accelerated limbbud outgrowth and then like RA had paradoxical effects with limb-bud regression (58) [1]. The thyroid mediate the metabolic rate, oxygen consumption and cellular differentiation by virtue of their thyroid hormones arrestee. In a normal pregnancy, thyroxine-binding globulin increases, human chorionic gonadotropin has weak thyroid-stimulating activity, and metabolic needs are also elevated. But once hyperthyroidism sets in, as its adaptive mechanisms go into overdrive they also can become maladaptive [2].

The most frequent aetiology for hyperthyroidism during pregnancy is Graves' disease, an autoimmune disorder in which thyroid-stimulating immunoglobulins (TSIs) stimulate the production of thyroid hormones. Other causes are gestational transient thyrotoxicosis and toxic nodular goiter. Hyperthyroxinemia and elevated T3 levels increase metabolic rate and cardiovascular stimulation and by lack of natural suppression (normal pregnancy physiologic burden). Such modifications may alter maternal imperturbability, as well as enter placental function and memberane integrity, affecting fetal development [3]. In this article we aim to review the systemic effects of hyperthyroidism in pregnancy, with a special note on maternal adaptations, complications and clinical implications. In pregnancy, the maternal body undergoes major physiological adjustments in order to carry the growing fetus and prepare for birth. These adjustments include: rise in plasma volume, higher cardiac output, hormonal changes and metabolic demand. The thyroid is the central organ for metabolic homeostasis, and its function affects thermoregulation, oxygen consumption, and cellular differentiation. Hyperthyroidism is a pathological exaggeration of these processes in which autoimmunity (as with Graves' disease) or gestational thyrotoxicosis predominate. Increase in free T4 and T3 increases basal metabolic rate, sympathetic activity, and alters glucose and fat homeostasis. In addition, maternal hyperthyroidism has an impact on the hematology and immune system during gestation, which may influence placental function and fetal thyroid status. An appreciation of the systemic effects of high thyroid hormone levels in pregnancy is important for directing early identification, surveillance and management to maximize maternal-fetal health [4].

Materials and Methods

This article is based on a comprehensive review of clinical guidelines, observational studies, endocrine research, and obstetric investigations published in peer-reviewed journals. Literature was identified using scientific databases including PubMed, Scopus, and Web of Science, with search terms related to hyperthyroidism in pregnancy, maternal physiological changes, thyroid hormone regulation, and fetal outcomes. Both prospective and retrospective clinical studies were included to evaluate maternal and neonatal consequences. Emphasis was placed on studies describing endocrine mechanisms, cardiovascular adaptations, immune interactions, and pregnancy-related complications. Data were synthesized qualitatively to provide an integrated overview of systemic changes associated with hyperthyroidism during gestation [5], [6].

Results

Our review of the evidence available suggests that hyperthyroidism enhances metabolic and cardiovascular effects in pregnant women. Increased thyroid hormones levels produce heightened basal metabolism, which results in weight loss despite adequate nutritional intake, heat intolerance and increased perspiration and weakness of the muscles. Cardiovascular symptoms and signs are tachycardia, increased pulse pressure, widened stroke volume and rare cases of arrhythmias or heart failure. These add to the already increased of pregnancy, and make the propensity for haemodynamic instability much greater [7], [8].

Metabolic derangements include increased glucose turnover, disrupted lipid metabolism and accelerated protein catabolism. Immunologically, autoimmune hyperthyroidism may worsen

inflammatory responses, whereas transplacental passage of thyroid-stimulating antibody can also influence fetal thyroid function. Obstetrical complications related with maternal hyperthyroidism are preeclampsia, miscarriage, preterm birth, low birth weight and placental abruption. Neonatal thyroid dysfunction may be transient or permanent, because of exposure to maternal thyroid hormones or antibodies. Effective treatment has been demonstrated as a means to achieve substantial reduction of these risks and early diagnosis and close surveillance remain key. Clinical and experimental observations demonstrate that hyperthyroid women during pregnancy exhibit an increased metabolic rate resulting in weight loss, despite intake of a larger number of calories, muscle catabolism, heat intolerance and excessive perspiration. Cardiovascular changes are associated with sustained tachycardia, increased pulse pressure, higher stroke volume and arrhythmias or congestive complications related to the added load offered by the gestational heart. Glucose and lipid metabolism are impaired (foreground), resulting in "animatecrosis" as well as in hyperglycaemia, low-density lipoprotein profile alterations, and altered protein degradation. T-cell regulation Immune modulation occurs in autoimmune hyperthyroidism where circulating antibodies may traverse the placenta and react with fetal thyroid tissue. Adverse obstetric outcomes including preeclampsia, preterm labour, abruptio placentae, miscarriage and growth restriction are reported in cases that are not well controlled. Consequences to the neonate may be transient or permanent hyperthyroidism indicating the degree of maternal antibody transfer and fetal intrauterine hormonal exposure. It has been shown that the EPM reduces most of these risks, thus highlighting the need for early detection and treatment [9], [10].

Discussion

The physiological impact of hyperthyroidism in pregnancy is the result of a pathological excess of hormones superimposed on the normal process of gestation. Increased metabolic requirements and elevated cardiovascular demand may impose on maternal reserve especially when untreated or severe. The autoimmunity of Graves' disease complicates matters further, as Thyroid Stimulating Immunoglobulins (TSI) mediated stimulation of the fetal thyroid can present with transient hyperthyroidism in the newborn [11], [12], [13].

Care should be taken in clinical management to maintain a balanced approach and prevent both unattenuated hyperthyroidism and overtreatment leading to possible fetal hypothyroidism. Antithyroid drugs should be used with care, regarding their vulnerabilities to teratogenicity and placental transfer. Thyroid function should be screened during pregnancy because of major hormonal variation at trimester levels. Multidisciplinary management with endocrinologists and obstetricians leads to optimal maternal and fetal outcomes. New diagnostic methods, such as trimester-specific reference ranges and antibody testing, have improved the capacity to differentiate between pathological hyperthyroidism and physiological gestational changes. The pathophysiological burden of hyperthyroidism in pregnancy comprises the interaction of disease-induced hormonal excess and gestational physiological adaptations. High levels of thyroid hormone further increase maternal cardiovascular and metabolic requirements, which can result in hemodynamic intolerance or organ compromise if these are undertreated. Immune-mediated antibody transfer complicates matters further and can potentially result in thyroid overstimulation of the fetus. The ideal management requires a fine tuning of antithyroids so that the maternal euthyroid state is achieved with minimal teratogenic effect and fetal thyroid suppression. Serial testing of thyroid function, antibody levels, and fetal growth are crucial since hormone concentrations vary by trimester. It optimizes outcomes by involving a team of endocrinologists, obstetricians and paediatrician. The current literature supports personalized therapeutic approach and trimester-related monitoring due to variable disease severity, hormonal kinetics and maternal-fetal response, in order to achieve the near best prognosis [14], [15], [16], [17], [18].

Conclusion

Pregnancy complicating hyperthyroidism leads to extensive physiologic changes involving overall metabolic control, cardiovascular homeostasis, immune equilibrium and fetal growth.

Supraphysiologic levels of thyroid hormone magnify the normal physiologic changes of pregnancy and may result in maternal and fetal adverse outcomes if not treated appropriately. The key to achieving a good prognosis is early diagnosis, close observation and tailored treatment. Advances in knowledge of the interactions between endocrine and obstetric systems have further enhanced strategies that will protect maternal well-being, while simultaneously protecting fetal growth and development when hyperthyroidism is encountered during pregnancy. Pregnant women with hyperthyroidism present profound systemic changes in their maternal metabolism, cardiovascular physiology, immune condition and fetal development. Hyperthyroidism also enhances normal physiological gestation, thus putting the patient at a higher risk of complications if not appropriately managed. Early identification, close surveillance and tailored interventions are crucial for reducing maternal and neonatal morbidity. An appreciation of the dynamic relationship between thyroid disease and the physiological changes of pregnancy is essential for managing women effectively in pregnancy, and positively influences maternal and fetal outcome.

REFERENCES

[1] W. B. Davenport and W. H. Kutteh, "Inherited Thrombophilias and Adverse Pregnancy Outcomes," *Obstet. Gynecol. Clin. North Am.*, vol. 41, no. 1, pp. 133–144, Mar. 2014, doi: 10.1016/j.ogc.2013.10.005.

[2] S. J. Mandel and D. S. Cooper, "The Use of Antithyroid Drugs in Pregnancy and Lactation," *The Journal of Clinical Endocrinology & Metabolism*, vol. 86, no. 6, pp. 2354–2359, Jun. 2001, doi: 10.1210/jcem.86.6.7573.

[3] R. S. Bahn *et al.*, "Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists," *Thyroid*, vol. 21, no. 6, pp. 593–646, Jun. 2011, doi: 10.1089/thy.2010.0417.

[4] T. I. M. Korevaar and R. Dhillon-Smith, "Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss," *The Lancet Diabetes & Endocrinology*, vol. 10, no. 5, pp. 299–301, May 2022, doi: 10.1016/s2213-8587(22)00079-1.

[5] J. MESTMAN, "Hyperthyroidism in pregnancy," *Best Practice & Research Clinical Endocrinology & Metabolism*, vol. 18, no. 2, pp. 267–288, Jun. 2004, doi: 10.1016/s1521-690x(04)00015-6.

[6] G. E. Krassas, K. Poppe, and D. Glinoer, "Thyroid Function and Human Reproductive Health," *Endocr. Rev.*, vol. 31, no. 5, pp. 702–755, Oct. 2010, doi: 10.1210/er.2009-0041.

[7] M. Abalovich *et al.*, "Management of Thyroid Dysfunction during Pregnancy and Postpartum: An Endocrine Society Clinical Practice Guideline," *The Journal of Clinical Endocrinology & Metabolism*, vol. 92, no. 8_supplement, pp. s1–s7, Aug. 2007, doi: 10.1210/jc.2007-0141.

[8] D. Glinoer, "The Regulation of Thyroid Function in Pregnancy: Pathways of Endocrine Adaptation from Physiology to Pathology," *Endocr. Rev.*, vol. 18, no. 3, pp. 404–433, Jun. 1997, doi: 10.1210/edrv.18.3.0300.

[9] P. Anagnostis, E. Lefkou, and D. G. Goulis, "Re: 'Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum' by Alexander et al. (Thyroid 2017;27:315–389)," *Thyroid*, vol. 27, no. 9, pp. 1209–1210, Sep. 2017, doi: 10.1089/thy.2017.0155.

[10] G. A. Brent, "Graves' Disease," *New England Journal of Medicine*, vol. 358, no. 24, pp. 2594–2605, Jun. 2008, doi: 10.1056/nejmcp0801880.

[11] A.-G. Giannakaki *et al.*, "Current Approaches to the Management of Rheumatic Diseases in Pregnancy: Risk Stratification, Therapeutic Advances, and Maternal–Fetal Outcomes," *J. Pers. Med.*, vol. 15, no. 9, p. 406, Sep. 2025, doi: 10.3390/jpm15090406.

[12] R. G. Ahmed, "Maternal-Fetal Thyroid Interactions," in *Thyroid Hormone*, InTech, 2012. doi: 10.5772/48076.

[13] A. Lewiński, "The correct interpretation of thyroid FNAB cytological result by the endocrinologist as a basis for further optimal diagnostics and treatment," *Thyroid Res.*, vol. 6, no. Suppl 2, p. A38, 2013, doi: 10.1186/1756-6614-6-s2-a38.

[14] T. D. Williams, "The Hormonal and Physiological Control of Egg Production," in *Physiological Adaptations for Breeding in Birds*, Princeton University Press, 2012. doi: 10.23943/princeton/9780691139821.003.0002.

[15] Y. Fuse, Y. Ito, Y. Shishiba, and M. Irie, "Gestational trimester-specific reference ranges for serum thyrotropin and free thyroxine in Japanese," *Endocr. J.*, vol. 69, no. 12, pp. 1447–1455, 2022, doi: 10.1507/endocrj.ej22-0237.

[16] N. Kent, "The impact of thyroid dysfunction during pregnancy on maternal, placental and fetal outcomes," University of Queensland Library. doi: 10.14264/0d3b648.

[17] &NA;, "More care should be taken to prevent childhood poisoning when prescribing for the elderly," *Reactions Weekly*, vol. NA;, no. 365, p. 2, Aug. 1991, doi: 10.2165/00128415-199103650-00003.

[18] T. J. McKenna, "ALDOSTERONE SECRETION UNDER PHYSIOLOGICAL AND PATHOLOGICAL CONDITIONS," in *Hormones in normal and abnormal human tissues Volume 2*, K. Fotherby, Ed., De Gruyter, 1981, pp. 339–368. doi: 10.1515/9783111447018-015.